

*Time*, top ten innovations of 2009

# Biobanks: Typology and Overview

David Winickoff, JD, MA Associate Professor of Bioethics & Society University of California, Berkeley

Tarrytown, NY | July 25, 2011



# **Biobanks:** Basic Definition

- Organized collections of human biol. material w/in health care systems & the med. sciences
- Often combined w/ some of the following info:
  - Personal, Medical (records), Genealogical, Environmental, Lifestyle
  - Richer the data set, more value
- Cf. "genomic database"

## Two main types

- 1. Collections of biological specimens from patients or donors
- 2. Population-based biobanks with biological samples from (parts of) the general public, with or without disease

(new IT and genotyping changes their value)

## Retrospective v. prospective distinction: distinction with a difference

- Unforeseen uses of previously collected material
  - Pathology collections (e.g., hospitals, army)
  - Dried blood spot collections
- Prospective collections
  - Population genomics (general population or special group)
    - UK Biobank, HapMap, Havasupai

# **Diverse agencies**

#### Public

 State agencies, state operated (V.A., Children's Health Study, U.K. Biobank)


#### Private

- Tissue purchase and lease
  operations
- Pharmaceutical companies
- Genetic testing companies
- Private clinics care orgs.

#### **Quasi public**

- Non-profit clinical care + research institutions (AMCs)
- Non-profit HMOs (Kaiser)
- Consumer organized disease banks
  (Genetic Alliance)

#### The potential value of disease biobanks



- Discovery of biomarkers using e.g. protein arrays, genomic analysis, gene expression analysis to:
  - Indicate present disease state
  - Predict future disease state
  - Predict responsiveness to drug therapy (companion diagnostics)
- Pharma interested in tissue banks as labs of "personalized medicine"

#### Potential value of population biobanks

- Useful to have large-scale collections of biological materials that can be genotyped, along with rich sets of phenotypic and environmental data
- Find factors of disease through correlations, and develop drug targets or genetic markers for PGx
- Disappointing results on common diseases from GWAS studies to date; movement toward "rare alleles" and sub-poputions

#### Limits on the research use of tissue:

**OHRP** Guidance on Biological Specimens (2008)

- 1. obtaining *identifiable* info or a specimen for research purposes = human subject research;
  - The act of collecting itself is considered research
  - Samples/info of the deceased don't qualify as "human subjects"
- 2. doing research on coded samples and or phenotypic info falls  $\rightarrow$  outside the regulations
  - (so long as contractual provisions in place preventing the investigator from access to the key)

## Regulatory gaps under the Common Rule

- Acceptability of broad consent with deidentification
- No right to withdraw sample or leave research
- No representation or formal accountability to participants
- No constraints on sale or lease of tissue

## My own work on biobank governance

- Research biobanks are at the center of a complex web of ethical interests and obligations involving:
  - 1. The aggregating institution
  - 2. Individual donor-participants
  - 3. The donor-participant collective
  - 4. The public
- Biobank aggregators are currently making important choices about how to invest the commercial and research value of biobanks
- We need more transparent constitutions (and power sharing?), because aggregating institutions may not adequately represent the other stakeholders